(Reuters) – LabCorp said on Thursday it has launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.
Information from the test about the disease-fighting ability of antibodies could be used in the development of COVID-19 vaccines, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)
